메뉴 건너뛰기




Volumn 10, Issue 12, 2009, Pages 1987-1994

Cytochrome P450 loss-of-function polymorphism genotyping on the Agilent Bioanalyzer and clinical application

Author keywords

Bioanalyzer; Cytochrome P450; DNA; Gene; Pharmacogenetics

Indexed keywords

CLONAZEPAM; CLOZAPINE; COCODAMOL; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; NORTRIPTYLINE; OLANZAPINE; VALPROIC ACID;

EID: 73649113841     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.127     Document Type: Article
Times cited : (8)

References (36)
  • 1
    • 1842689283 scopus 로고    scopus 로고
    • Genes, race and drugs
    • Bevan D: Genes, race and drugs. Clin. Invest. Med. 27(1), 5-6 (2004).
    • (2004) Clin. Invest. Med , vol.27 , Issue.1 , pp. 5-6
    • Bevan, D.1
  • 2
    • 4444268163 scopus 로고    scopus 로고
    • Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms
    • Kim K, Johnson JA, Derendorf H: Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J. Clin. Pharmacol. 44(10), 1083-1105 (2004).
    • (2004) J. Clin. Pharmacol , vol.44 , Issue.10 , pp. 1083-1105
    • Kim, K.1    Johnson, J.A.2    Derendorf, H.3
  • 3
    • 59549103789 scopus 로고    scopus 로고
    • Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A: Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet. Genomics 19(2), 170-179 (2009). Aimed at describing the worldwide distribution of genetic variation and frequency for the most important CYP2C9, CYP2C19 and CYP2D6 genetic variants. It was shown how demographic history could affect pharmacogenetic variation at a microgeographic scale by analyzing at the regional.
    • Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A: Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet. Genomics 19(2), 170-179 (2009). Aimed at describing the worldwide distribution of genetic variation and frequency for the most important CYP2C9, CYP2C19 and CYP2D6 genetic variants. It was shown how demographic history could affect pharmacogenetic variation at a microgeographic scale by analyzing at the regional.
  • 4
    • 63449117825 scopus 로고    scopus 로고
    • Takeuchi F, Mcginnis R, Bourgeois S et al.: A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), E1000433 (2009). Description of the first genome-wide association study whose sample size was sufficiently powered to detect genome-wide significance for polymorphisms that modestly altered therapeutic drug dose.
    • Takeuchi F, Mcginnis R, Bourgeois S et al.: A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), E1000433 (2009). Description of the first genome-wide association study whose sample size was sufficiently powered to detect genome-wide significance for polymorphisms that modestly altered therapeutic drug dose.
  • 5
    • 59149104827 scopus 로고    scopus 로고
    • Pharmacogenomics and personalized use of drugs
    • Wang JF, Wei DQ, Chou KC: Pharmacogenomics and personalized use of drugs. Curr. Top. Med. Chem. 8(18), 1573-1579 (2008).
    • (2008) Curr. Top. Med. Chem , vol.8 , Issue.18 , pp. 1573-1579
    • Wang, J.F.1    Wei, D.Q.2    Chou, K.C.3
  • 6
    • 63349098150 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 polymorphism and Clopidogrel after MI
    • 373 9670, 1171; author reply 1172-1173
    • Bhattacharyya S, Rakhit R: Cytochrome P450 2C19 polymorphism and Clopidogrel after MI. Lancet 373 (9670), 1171; author reply 1172-1173 (2009).
    • (2009) Lancet
    • Bhattacharyya, S.1    Rakhit, R.2
  • 7
    • 70349910091 scopus 로고    scopus 로고
    • The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
    • Bijl MJ, van Schaik RH, Lammers LA et al.: The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res. Treat. 118(1), 125-130 (2009).
    • (2009) Breast Cancer Res. Treat , vol.118 , Issue.1 , pp. 125-130
    • Bijl, M.J.1    van Schaik, R.H.2    Lammers, L.A.3
  • 8
    • 57749198655 scopus 로고    scopus 로고
    • Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in β-blocker users
    • Bijl MJ, Visser LE, van Schaik RH et al.: Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in β-blocker users. Clin. Pharmacol. Ther. 85(1), 45-50 (2009).
    • (2009) Clin. Pharmacol. Ther , vol.85 , Issue.1 , pp. 45-50
    • Bijl, M.J.1    Visser, L.E.2    van Schaik, R.H.3
  • 10
    • 57149135263 scopus 로고    scopus 로고
    • Pharmacogenetic testing in psychiatry: A review of features and clinical realities
    • Thorough description of the first generation of pharmacogenetic tests that are potentially useful in psychiatry. The future of these and other pharmacogenetic tests in psychiatry is discussed
    • De Leon J, Arranz MJ, Ruano G: Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin. Lab. Med. 28(4), 599-617 (2008). Thorough description of the first generation of pharmacogenetic tests that are potentially useful in psychiatry. The future of these and other pharmacogenetic tests in psychiatry is discussed.
    • (2008) Clin. Lab. Med , vol.28 , Issue.4 , pp. 599-617
    • De Leon, J.1    Arranz, M.J.2    Ruano, G.3
  • 11
    • 42949151507 scopus 로고    scopus 로고
    • Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis
    • Ercan B, Ayaz L, Cicek D, Tamer L: Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. Cell Biochem. Funct. 26(3), 309-313 (2008).
    • (2008) Cell Biochem. Funct , vol.26 , Issue.3 , pp. 309-313
    • Ercan, B.1    Ayaz, L.2    Cicek, D.3    Tamer, L.4
  • 12
    • 67749114265 scopus 로고    scopus 로고
    • CYP2D6 and tamoxifen: DNA matters in breast cancer
    • Hoskins JM, Carey LA, Mcleod HL: CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9(8), 576-586 (2009).
    • (2009) Nat. Rev. Cancer , vol.9 , Issue.8 , pp. 576-586
    • Hoskins, J.M.1    Carey, L.A.2    Mcleod, H.L.3
  • 13
    • 60849097257 scopus 로고    scopus 로고
    • Estimation of the warfarin dose with clinical and pharmacogenetic data
    • Klein TE, Altman RB, Eriksson N et al.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
    • (2009) N. Engl. J. Med , vol.360 , Issue.8 , pp. 753-764
    • Klein, T.E.1    Altman, R.B.2    Eriksson, N.3
  • 14
    • 66749132507 scopus 로고    scopus 로고
    • CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: A retrospective matched case-control study
    • Kobylecki CJ, Jakobsen KD, Hansen T, Jakobsen IV, Rasmussen HB, Werge T: CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology 59(4), 222-226 (2009).
    • (2009) Neuropsychobiology , vol.59 , Issue.4 , pp. 222-226
    • Kobylecki, C.J.1    Jakobsen, K.D.2    Hansen, T.3    Jakobsen, I.V.4    Rasmussen, H.B.5    Werge, T.6
  • 15
    • 58149231251 scopus 로고    scopus 로고
    • The clinical impact of pharmacogenetics on the treatment of epilepsy
    • Loscher W, Klotz U, Zimprich F, Schmidt D: The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 50(1), 1-23 (2009).
    • (2009) Epilepsia , vol.50 , Issue.1 , pp. 1-23
    • Loscher, W.1    Klotz, U.2    Zimprich, F.3    Schmidt, D.4
  • 16
    • 58749094444 scopus 로고    scopus 로고
    • Cytochrome p-450 polymorphisms and response to Clopidogrel
    • Mega JL, Close SL, Wiviott SD et al.: Cytochrome p-450 polymorphisms and response to Clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009).
    • (2009) N. Engl. J. Med , vol.360 , Issue.4 , pp. 354-362
    • Mega, J.L.1    Close, S.L.2    Wiviott, S.D.3
  • 17
    • 48549090855 scopus 로고    scopus 로고
    • CYP2C19 genotypes and Helicobacter pylori eradication
    • Sheu BS, Fock KM: CYP2C19 genotypes and Helicobacter pylori eradication. J. Gastroenterol. Hepatol. 23(8 Pt 1), 1163 (2008).
    • (2008) J. Gastroenterol. Hepatol , vol.23 , Issue.8 PART 1 , pp. 1163
    • Sheu, B.S.1    Fock, K.M.2
  • 18
    • 67650602114 scopus 로고    scopus 로고
    • Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers
    • Vormfelde SV, Brockmoller J, Bauer S et al.: Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin. Pharmacol. Ther. 86(1), 54-61 (2009).
    • (2009) Clin. Pharmacol. Ther , vol.86 , Issue.1 , pp. 54-61
    • Vormfelde, S.V.1    Brockmoller, J.2    Bauer, S.3
  • 19
    • 59149104827 scopus 로고    scopus 로고
    • Pharmacogenomics and personalized use of drugs
    • Wang JF, Wei DQ, Chou KC: Pharmacogenomics and personalized use of drugs. Curr. Top. Med. Chem. 8(18), 1573-1579 (2008).
    • (2008) Curr. Top. Med. Chem , vol.8 , Issue.18 , pp. 1573-1579
    • Wang, J.F.1    Wei, D.Q.2    Chou, K.C.3
  • 20
    • 58849130987 scopus 로고    scopus 로고
    • CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole
    • Weiss J, Ten Hoevel MM, Burhenne J et al.: CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J. Clin. Pharmacol. 49(2), 196-204 (2009).
    • (2009) J. Clin. Pharmacol , vol.49 , Issue.2 , pp. 196-204
    • Weiss, J.1    Ten Hoevel, M.M.2    Burhenne, J.3
  • 21
    • 47749105202 scopus 로고    scopus 로고
    • Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment
    • Xu Y, Sun Y, Yao L et al.: Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann. Oncol. 19(8), 1423-1429 (2008).
    • (2008) Ann. Oncol , vol.19 , Issue.8 , pp. 1423-1429
    • Xu, Y.1    Sun, Y.2    Yao, L.3
  • 22
    • 68049129639 scopus 로고    scopus 로고
    • Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia
    • Yagihashi T, Mizuno M, Chino B et al.: Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. Hum. Psychopharmacol. 24(4), 301-308 (2009).
    • (2009) Hum. Psychopharmacol , vol.24 , Issue.4 , pp. 301-308
    • Yagihashi, T.1    Mizuno, M.2    Chino, B.3
  • 23
    • 55949102330 scopus 로고    scopus 로고
    • Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for helicobacter pylori eradication: A meta-analysis
    • Zhao F, Wang J, Yang Y et al.: Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for helicobacter pylori eradication: a meta-analysis. Helicobacter 13(6), 532-541 (2008).
    • (2008) Helicobacter , vol.13 , Issue.6 , pp. 532-541
    • Zhao, F.1    Wang, J.2    Yang, Y.3
  • 24
    • 59149096567 scopus 로고    scopus 로고
    • The amplichip CYP450 test: Cytochrome P450 2D6 genotype assessment and phenotype prediction
    • Rebsamen MC, Desmeules J, Daali Y et al.: The amplichip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 9(1), 34-41 (2009).
    • (2009) Pharmacogenomics J , vol.9 , Issue.1 , pp. 34-41
    • Rebsamen, M.C.1    Desmeules, J.2    Daali, Y.3
  • 25
    • 34249084393 scopus 로고    scopus 로고
    • Chetty M, Murray M: CYP-mediated clozapine interactions: how predictable are they? Curr. Drug Metab. 8(4), 307-313 (2007). Pharmacokinetic interactions can have a significant impact on drug response. Those involving clozapine are discussed. The majority of the interactions with clozapine are reported to be mediated by cytochrome P450 enzymes.
    • Chetty M, Murray M: CYP-mediated clozapine interactions: how predictable are they? Curr. Drug Metab. 8(4), 307-313 (2007). Pharmacokinetic interactions can have a significant impact on drug response. Those involving clozapine are discussed. The majority of the interactions with clozapine are reported to be mediated by cytochrome P450 enzymes.
  • 27
    • 0036859174 scopus 로고    scopus 로고
    • Cardiac risk at the onset of treatment in patients treated with benzodiazepines and clozapine
    • Borentain S, Millet B, Olie JP: Cardiac risk at the onset of treatment in patients treated with benzodiazepines and clozapine. Eur. Psychiatry 17(7), 419-420 (2002).
    • (2002) Eur. Psychiatry , vol.17 , Issue.7 , pp. 419-420
    • Borentain, S.1    Millet, B.2    Olie, J.P.3
  • 28
    • 0029617339 scopus 로고
    • Delirium associated with clozapine and benzodiazepine combinations
    • Jackson CW, Markowitz JS, Brewerton TD: Delirium associated with clozapine and benzodiazepine combinations. Ann. Clin. Psychiatry 7 (3), 139-141 (1995).
    • (1995) Ann. Clin. Psychiatry , vol.7 , Issue.3 , pp. 139-141
    • Jackson, C.W.1    Markowitz, J.S.2    Brewerton, T.D.3
  • 29
    • 0028201765 scopus 로고
    • Sudden death after intravenous application of lorazepam in a patient treated with clozapine
    • Klimke A, Klieser E: Sudden death after intravenous application of lorazepam in a patient treated with clozapine. Am. J. Psychiatry 151(5), 780 (1994).
    • (1994) Am. J. Psychiatry , vol.151 , Issue.5 , pp. 780
    • Klimke, A.1    Klieser, E.2
  • 30
    • 0023108698 scopus 로고
    • Tricyclic antidepressant overdose. A review
    • Frommer DA, Kulig KW, Marx JA, Rumack B: Tricyclic antidepressant overdose. A review. JAMA 257(4), 521-526 (1987).
    • (1987) JAMA , vol.257 , Issue.4 , pp. 521-526
    • Frommer, D.A.1    Kulig, K.W.2    Marx, J.A.3    Rumack, B.4
  • 31
    • 0028013158 scopus 로고
    • Polymorphism in the metabolism of drugs, including antidepressant drugs: Comments on phenotyping
    • Coutts RT: Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping. J. Psychiatry Neurosci. 19(1), 30-44 (1994).
    • (1994) J. Psychiatry Neurosci , vol.19 , Issue.1 , pp. 30-44
    • Coutts, R.T.1
  • 32
    • 0023105260 scopus 로고
    • Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system
    • Bryant SG, Fisher S, Kluge RM: Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system. J. Clin. Psychopharmacol. 7(2), 78-82 (1987).
    • (1987) J. Clin. Psychopharmacol , vol.7 , Issue.2 , pp. 78-82
    • Bryant, S.G.1    Fisher, S.2    Kluge, R.M.3
  • 33
    • 65249112850 scopus 로고    scopus 로고
    • Billups SJ, Delate T, Dugan D: Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations. Pharmacoepidemiol. Drug Saf. 18(3), 253-257 (2009). Attempt to quantify the effect of clinical and demographic factors on the risk of elevated and toxic tricyclic antidepressant plasma concentrations and to describe the incidence of elevated and toxic tricyclic antidepressant.
    • Billups SJ, Delate T, Dugan D: Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations. Pharmacoepidemiol. Drug Saf. 18(3), 253-257 (2009). Attempt to quantify the effect of clinical and demographic factors on the risk of elevated and toxic tricyclic antidepressant plasma concentrations and to describe the incidence of elevated and toxic tricyclic antidepressant.
  • 34
    • 7544234883 scopus 로고    scopus 로고
    • A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication
    • Lee SY, Ki CS, Hong KS, Kim JW: A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication. J. Korean Med. Sci. 19(5), 750-752 (2004).
    • (2004) J. Korean Med. Sci , vol.19 , Issue.5 , pp. 750-752
    • Lee, S.Y.1    Ki, C.S.2    Hong, K.S.3    Kim, J.W.4
  • 35
    • 0037789293 scopus 로고    scopus 로고
    • A differential response to nortriptyline and fluoxetine in melancholic depression: The importance of age and gender
    • Joyce PR, Mulder RT, Luty SE, Mckenzie JM, Rae AM: A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender. Acta Psychiatr. Scand. 108(1), 20-23 (2003).
    • (2003) Acta Psychiatr. Scand , vol.108 , Issue.1 , pp. 20-23
    • Joyce, P.R.1    Mulder, R.T.2    Luty, S.E.3    Mckenzie, J.M.4    Rae, A.M.5
  • 36
    • 0035987702 scopus 로고    scopus 로고
    • Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline
    • Joyce PR, Mulder RT, Luty SE et al.: Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust. NZ J. Psychiatry 36(3), 384-391 (2002).
    • (2002) Aust. NZ J. Psychiatry , vol.36 , Issue.3 , pp. 384-391
    • Joyce, P.R.1    Mulder, R.T.2    Luty, S.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.